This article is more than 5 years old. Information may no longer be current.

Spark Therapeutics posts first-quarter net loss of $52.3 million

Issue: July 25, 2017

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Spark Therapeutics reported a net loss of $52.3 million, or $1.70 per share, in the first quarter of 2017 compared with a net loss of $25.6 million, or $0.95 per share, in the first quarter of 2016.

Research and development costs increased from $18.2 million in 2016’s first quarter to $32.7 million this year, which was attributed to an increase in personnel and expenses related to studies to support launch preparation activities for voretigene neparvovec, according to a company press release.

General and administrative expenses for the quarter were $21.4 million compared with $8.9 million in 2016.

The company reported $285.4 million in cash, cash equivalents and marketable securities as of March 31.